At a Glance
  • Status: Completed Consortium
  • Year Launched: 2005
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Disease focus:
    Alzheimer's Disease
  • Location: Europe

Abstract

AddNeuroMed, as part of InnoMed, is a precursor of the Innovative Medicines Initiative (IMI). AddNeuroMed is a cross-European study, funded by the European Union and members of the European Federation for Pharmaceutical Industries and Associations (EFPIA) and designed to find biomarkers, or tests, for Alzheimer’s disease.

Mission

The AddNeuroMed objectives are to produce and improve experimental models of Alzheimer’s disease for biomarker discovery and to identify a biomarker for Alzheimer’s disease suitable for diagnosis, prediction, and monitoring disease progression for use in clinical trials and in clinical practice.

Consortium History

AddNeuroMed is involved in multiple preclinical studies including mice models, rat model, drosophila models, bioinformatics driven, and imaging.

Structure & Governance

AddNeuroMed is governed by IMI.

Financing

AddNeuroMed is funded by the European Union and EFPIA members.

Intellectual Property

The IMI Intellectual Property (IP) Policy governs the IP regime of all projects funded by the IMI Joint Undertaking (JU). To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by e-mailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at the following address: http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

AddNeuroMed is still collecting data. It welcomes collaborations and requests to access these data as the study progresses. The baseline data set was scheduled to be completed and locked in 2008 and become available to researchers by 2009. Requests to access these data will be reviewed by the scientific projects committee. In keeping with IMI policy, the AddNeuroMed project has up to one year after completion to disseminate IP or data created by the project.

Impact/Accomplishment

Finding a biomarker would help in clinical practice by empowering people with possible dementia and their families with more accurate information and would help in the discovery of new treatments by making clinical trials more effective. AddNeuroMed has preclinical and clinical components in addition to platform technologies in separate work-packages. Preclinical models of disease are used to find potential biomarkers, which are then validated in human studies. The human studies are used to discover novel biomarkers, which are then validated in preclinical models.

Points of Contact

Simon Lovestone
phone: +44 (20) 7848 0239 / 0050
email: s.lovestone@iop.kcl.ac.uk

Paul Francis
phone: +44 (20) 7848 6269
email: paul.francis@kcl.ac.uk

Sponsors & Partners

Aristotle University of Thessaloniki

Centre Hospitalier Universitaire de Toulouse

European Federation for Pharmaceutical Industries and Associations (EFPIA)

European Union

Innovative Medicines Initiative

King’s College, London

Università  degli Studi di Perugia

University of Kuopio

University of Lodz


Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.